Showing results (71-80 of 377) with videos related to
Sort By:
Pageof 38
Healthcare (Basel, Switzerland)|July 16, 2016
Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer SupportChalanda Evans, Rebekah J Hamilton, Kenneth P Tercyak, et al.Familial Cancer|November 11, 2017
Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel populationSuzanne C O'Neill, Chalanda Evans, Rebekah J Hamilton, et al.JNCI Cancer Spectrum|April 28, 2020
Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast CancerJinani Jayasekera, Joseph A Sparano, Robert Gray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testingMarc D Schwartz, Elizabeth Kaufman, Beth N Peshkin, et al.Journal of Cancer Epidemiology|August 18, 2012
Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RSNadiyah Sulayman, Elizabeth Spellman, Kristi D Graves, et al.Contemporary Clinical Trials|January 23, 2016
An exercise trial to reduce cancer related fatigue in African American breast cancer patients undergoing radiation therapy: Design, rationale, and methodsChiranjeev Dash, Pamela D Randolph-Jackson, Claudine Isaacs, et al.Hormones & Cancer|July 16, 2011
Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohortCatherine Schairer, Catherine A McCarty, Claudine Isaacs, et al.Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.Cancer Chemotherapy and Pharmacology|September 21, 2019
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignanciesFilipa Lynce, Hongkun Wang, Emanuel F Petricoin, et al.Pageof 38